title: Bevacizumab (Avastin) eye drops inhibit corneal neovascularization.
abstract: BACKGROUND
  To analyze the ability of bevacizumab (Avastin) eye drops to inhibit corneal neovascularization.
  
  
  METHODS
  interventional case series involving five patients (age: 42 +/- 14 years).
  
  
  METHODS
  Patients with aggressive corneal neovascularisation not responding to conventional therapy were treated with bevacizumab (Avastin) eye drops (5x/day; 5 mg/ml) for 0.5 to 6 months (mean: 3.6 +/- 2; four patients with limbal stem cell deficiency [three due to chemical burns and one inherited] and one after perforating keratoplasty).
  
  
  RESULTS
  Bevacizumab eye drops were well tolerated without obvious corneal side-effects. All five patients showed a reduction in the neovascularized area (decrease 48 +/- 28%; 13-75%).
  
  
  CONCLUSIONS
  Bevacizumab eye drops seem to inhibit corneal neovascularization without obvious corneal epithelial side-effects.
authors.affiliation: Department of Ophthalmology, Friedrich-Alexander University Erlangen-Nürnberg, Schwabachanlage 6, Erlangen, Germany.
authors.forename: Felix
authors.initials: F
authors.lastname: Bock
authors.forename: Yanyan
authors.initials: Y
authors.lastname: König
authors.forename: Friedrich
authors.initials: F
authors.lastname: Kruse
authors.forename: Martin
authors.initials: M
authors.lastname: Baier
authors.forename: Claus
authors.initials: C
authors.lastname: Cursiefen
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016510:Corneal Neovascularization / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage*; D042461:Vascular Endothelial Growth Factor A
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009883:Ophthalmic Solutions; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab